Navigation Links
Cardiac Science Announces Full Shipment of 'Crash Cart' Defibrillator
Date:10/22/2007

Defibrillator to be Sold Exclusively by GE Healthcare Expands Company

Offerings within Worldwide Hospital Market

BOTHELL, Wash., Oct. 22 /PRNewswire-FirstCall/ -- Cardiac Science Corporation (Nasdaq: CSCX), a global leader in advanced cardiac monitoring and defibrillation products, announced today it has completed its pilot program and has begun full shipments of its new "crash cart" defibrillator as part of an existing agreement with GE Healthcare (GE).

(Logo: http://www.newscom.com/cgi-bin/prnh/20050913/SFTU139LOGO )

The crash cart defibrillator-monitor is designed specifically for use by medical professionals to respond to cardiac emergencies in hospital settings. The new defibrillator will be manufactured by Cardiac Science and sold exclusively by GE to hospitals in the United States and Canada as the Cardiac Science Powerheart(R) ECD, and to customers outside North America as the GE Responder(TM)2000. GE will be featuring the product at the upcoming American Heart Association (AHA) and MEDICA trade shows in November.

"The new defibrillator-monitor meets the demanding requirements for hospital use, and demonstrates our continuing efforts to broaden our products and services. We believe this crash cart is a compelling offering for the estimated $300 million worldwide hospital defibrillator-monitor market," said John Hinson, Cardiac Science's Chief Executive Officer. "Our partnership with GE will give us the reach and scope to effectively penetrate that market, and contribute to our goal of saving more lives. If the initial indications are a measure of market acceptance, we believe this product will very successful for both companies."

The defibrillators are currently available outside of North America, and are expected to be available within the U.S. and Canada during the first quarter of 2008.

About the new defibrillator-monitor

The new defibrillator-monitor is a lightweight, rugged and portable device designed for use by professionals in medically-supervised environments to respond to cardiac emergencies. Similar to Cardiac Science's line of portable AEDs, the new device is extremely easy to use, while still incorporating advanced resuscitation and pacing therapies for use by the trained medical professional.

The new defibrillator-monitor incorporates Cardiac Science's patented STAR(R) biphasic escalating shock energy technology which automatically adjusts the magnitude of the defibrillation shock based upon each patient's unique body type. It also employs Cardiac Science's patented RHYTHMx(R) software, which provides heart rhythm analysis and shock advice to effectively address life-threatening arrhythmias.

About Cardiac Science Corporation

Cardiac Science is truly at the heart of saving lives. The Company develops, manufactures, and markets a family of advanced diagnostic and therapeutic cardiology devices and systems, including AEDs, electrocardiographs, stress test systems, Holter monitoring systems, hospital defibrillators, cardiac rehabilitation telemetry systems, patient monitor - defibrillators and cardiology data management systems. Cardiac Science also sells a variety of related products and consumables, and provides a comprehensive portfolio of training, maintenance and support services. The Company is the successor to various entities that have owned and operated cardiology-related businesses that sold products under the trusted brand names Burdick(R), Powerheart(R), and Quinton(R). Cardiac Science is headquartered in Bothell, WA, and also has operations in Lake Forest, California; Deerfield, Wisconsin; Shanghai, China and Manchester, United Kingdom.

Forward Looking Statements

This press release contains forward-looking statements, including, but not limited to, those which infer that Cardiac Science Corporation's future revenue and profits may grow as a result of sales of defibrillation products. These statements and their underlying assumptions involve a number of risks and uncertainties and are not guarantees of future performance. These are forward-looking statements for purposes of the safe harbor provisions under the Private Securities Litigation Reform Act of 1995. The words "believe," "expect," "intend," anticipate," variations of such words, and similar expressions identify forward-looking statements, but their absence does not mean that the statement is not forward-looking. Actual results may vary significantly from the results expressed or implied in such statements. Factors that could cause or contribute to such varying results and other risks are more fully described in the Annual Report on Form 10-K filed by Cardiac Science Corporation for the year ended December 31, 2006. Cardiac Science Corporation undertakes no duty or obligation to update the information provided herein.

Cardiac Science Contact

Mike Matysik

Cardiac Science Corp.

Sr. Vice President and CFO

(425) 402-2009

Cardiac Science Investor/Media Contact:

EVC Group, Inc.

Douglas Sherk/Jenifer Kirtland (Investors)

415-896-6820

Steve DiMattia (Media)

(646) 277-8706


'/>"/>
SOURCE Cardiac Science Corporation
Copyright©2007 PR Newswire.
All rights reserved

Related medicine news :

1. Thyroid hormone treatment hastens recovery after cardiac surgery
2. Gene HPA-2 Met linked to cardiac arrest
3. Defibrillators In Public Places Will Help Cardiac Patients
4. Supplement helps cardiac surgery
5. Cardiac diseases develop early
6. Latest device for cardiac revival under test
7. Bone marrow stem cells may help repair cardiac tissues
8. Heart problems detected better with a Cardiac MRI
9. Cardiac events better treated with intense cholesterol-lowering regime
10. Sudden Cardiac Death due to inherited Heart Disease
11. Vasopressin Found To Boost Survival In Sudden Cardiac arrest
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/25/2017)... (PRWEB) , ... April 25, ... ... based in Newport Beach, California, committed to raising awareness for Duchenne muscular ... results from its randomized CAP-1002 (cardiosphere-derived cells) Phase I/II HOPE clinical trial ...
(Date:4/25/2017)... ... April 25, 2017 , ... As President Trump challenges ... for how his administration could impact the employee benefits industry. James Slotnick, AVP, ... most likely to make it through Congress. His discussion will focus on the ...
(Date:4/25/2017)... ... April 25, 2017 , ... The doctors at Wall Centre Dental ... with dental fear and require sedation to receive dental care. The doctors offer three ... procedures, from hygienic cleanings to oral surgery, at their dental office in Vancouver. Wall ...
(Date:4/25/2017)... ... April 25, 2017 , ... Patients who would like ... in a fraction of the time as traditional braces – Wilckodontics®. Dr. Victoria ... now offers this revolutionary treatment with or without a referral. , Wilckodontics ...
(Date:4/25/2017)... ... April 25, 2017 , ... ... in unveiling cutting-edge birth defects research related to Zika virus during pregnancy, as ... premier society for this important science. , The Teratology Society ...
Breaking Medicine News(10 mins):
(Date:4/19/2017)... 2017 Companion animal ... in pets such as canine, avian and feline. ... types such as Attenuated Live Vaccines, Conjugate Vaccines, ... and Recombinant Vaccines. Attenuated live vaccines are derived ... which have been weakend under laboratory conditions. Conjugate ...
(Date:4/19/2017)... , April 19, 2017  SARES•REGIS Group leased ... is developing at Conejo Spectrum Business Park in ... Atara Biotherapeutics, Inc. , a biopharmaceutical company ... life-threatening diseases that have been underserved by scientific ... therapies for cancer, autoimmune and infectious disease. ...
(Date:4/18/2017)... , April 18, 2017 Viverae ® , ... announce the integration of IBM ® Watson Campaign ... deliver targeted communications for a personalized experience. Through digital ... on their health in real time. The enhanced experience ... most to members, wherever they are in their journey ...
Breaking Medicine Technology: